Paricalcitol

( DrugBank: Paricalcitol / KEGG DRUG: Paricalcitol )


5 diseases
IDDisease name (Link within this page)Number of trials
19Lysosomal storage disease1
66IgA nephropathy1
218Alport syndrome1
IDDisease name (Link within this page)Number of trials
238Vitamin D-resistant rickets1
298Hereditary pancreatitis1

19. Lysosomal storage disease


Clinical trials : 1,038 / Drugs : 873 - (DrugBank : 121) / Drug target genes : 63 - Drug target pathways : 195 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 407 / Drugs : 342 - (DrugBank : 73) / Drug target genes : 40 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

218. Alport syndrome


Clinical trials : 47 / Drugs : 49 - (DrugBank : 23) / Drug target genes : 8 - Drug target pathways : 46 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

238. Vitamin D-resistant rickets


Clinical trials : 34 / Drugs : 26 - (DrugBank : 11) / Drug target genes : 3 - Drug target pathways : 16 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

298. Hereditary pancreatitis


Clinical trials : 126 / Drugs : 210 - (DrugBank : 59) / Drug target genes : 65 - Drug target pathways : 161 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries